CN116421514A - Acne-removing composition and eye cream for non-irritation of eyes, and preparation method and application of acne-removing composition and eye cream - Google Patents
Acne-removing composition and eye cream for non-irritation of eyes, and preparation method and application of acne-removing composition and eye cream Download PDFInfo
- Publication number
- CN116421514A CN116421514A CN202310301930.XA CN202310301930A CN116421514A CN 116421514 A CN116421514 A CN 116421514A CN 202310301930 A CN202310301930 A CN 202310301930A CN 116421514 A CN116421514 A CN 116421514A
- Authority
- CN
- China
- Prior art keywords
- acne
- skin
- parts
- materials
- eye cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 54
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000006071 cream Substances 0.000 title claims abstract description 31
- 206010015946 Eye irritation Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 53
- 239000000284 extract Substances 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 24
- 230000003255 anti-acne Effects 0.000 claims abstract description 22
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 18
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 12
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 12
- MQWLIFWNJWLDCI-UHFFFAOYSA-L zinc;carbonate;hydrate Chemical compound O.[Zn+2].[O-]C([O-])=O MQWLIFWNJWLDCI-UHFFFAOYSA-L 0.000 claims abstract description 12
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 9
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims abstract description 9
- 229960000458 allantoin Drugs 0.000 claims abstract description 9
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 8
- 231100000344 non-irritating Toxicity 0.000 claims abstract description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims description 54
- 239000003921 oil Substances 0.000 claims description 33
- 238000001816 cooling Methods 0.000 claims description 24
- 239000013067 intermediate product Substances 0.000 claims description 22
- 239000003755 preservative agent Substances 0.000 claims description 16
- 230000002335 preservative effect Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 13
- 239000004519 grease Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 230000007794 irritation Effects 0.000 claims description 13
- 239000002562 thickening agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 239000002738 chelating agent Substances 0.000 claims description 11
- 229910021645 metal ion Inorganic materials 0.000 claims description 11
- -1 pH adjusters Substances 0.000 claims description 10
- 239000003381 stabilizer Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000012937 correction Methods 0.000 claims description 9
- 150000005846 sugar alcohols Polymers 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 241000563984 Ampelopsis Species 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 229940049964 oleate Drugs 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 235000002195 Nymphaea caerulea Nutrition 0.000 claims description 4
- 244000203593 Piper nigrum Species 0.000 claims description 4
- 235000008184 Piper nigrum Nutrition 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 229940100515 sorbitan Drugs 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 3
- 241001673966 Magnolia officinalis Species 0.000 claims description 3
- 244000007853 Sarothamnus scoparius Species 0.000 claims description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- FSEJJKIPRNUIFL-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)COC(=O)CCCCCCCCCCCCCCCCC FSEJJKIPRNUIFL-UHFFFAOYSA-N 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 244000058734 Nymphaea stellata Species 0.000 claims 1
- 235000016428 Nymphaea stellata Nutrition 0.000 claims 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 1
- 229960003291 chlorphenamine Drugs 0.000 claims 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 229950004959 sorbitan oleate Drugs 0.000 claims 1
- 231100000013 eye irritation Toxicity 0.000 abstract description 7
- 241000219099 Parthenocissus quinquefolia Species 0.000 abstract description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 2
- 241001313855 Bletilla Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 55
- 239000000047 product Substances 0.000 description 52
- 238000012360 testing method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 13
- 239000002994 raw material Substances 0.000 description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- 230000028327 secretion Effects 0.000 description 9
- 210000002374 sebum Anatomy 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 208000020154 Acnes Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 240000007817 Olea europaea Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000003837 chick embryo Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 240000009085 Nymphaea caerulea Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 244000248825 Peltandra virginica Species 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 229940057429 sorbitan isostearate Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000011376 Leptospermum laevigatum Species 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000821 endpoints of toxicity testing Toxicity 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229940082450 magnolia officinalis bark extract Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses an anti-acne composition for eye irritation, eye cream and a preparation method and application thereof, wherein the anti-acne composition is prepared from 0.01-5 parts of lotus oil-control anti-inflammatory factors, 0.01-5 parts of modified skin ecological factors, 0.05-0.5 part of allantoin, 0.01-5 parts of zinc carbonate hydroxide, 0.01-0.5 part of pearl powder, 0.01-0.5 part of amber powder, 0.01-0.5 part of borneol, 0.001-1 part of Japanese ampelopsis root extract, 0.001-1 part of bletilla root extract and 0.001-1 part of poria sclerotium extract, and the anti-acne eye cream can be prepared by adding proper auxiliary materials. The acne-removing composition and the eye cream provided by the invention have high applicability to Zhou Qu acne, are mild and non-irritating, and can be used for removing acne, repairing and moisturizing; in addition, the preparation method provided by the invention is simple and is easy for mass production of products.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to an anti-acne composition for non-irritation of eyes, eye cream and a preparation method and application thereof.
Background
Sebaceous glands are an important gland on the skin and are widely distributed throughout the body except for the hands and soles, with the most skin being on the face, chest and back. The skin is normally metabolized, the sebaceous glands are secreting sebum at all times, and the secretion amount is increased along with the rise of the temperature, so that the secretion is particularly severe in summer; meanwhile, the sebaceous gland secretion capacity of different people is different, and the secretion of human grease of oily skin is naturally vigorous. However, excessive secretion can cause pores to grow large and bacteria to grow large, thereby causing numerous acnes to develop on the face.
The cases of long acnes around the eyes are relatively rare, but with the increasing attention of consumers to facial management, the problems of anxiety, depression, lack of confidence, body image and the like are caused wherever the acnes are caused, so that solutions for the problems are very necessary for consumers.
The structure of the eye skin is thinner than that of other parts, such as the skin of the face, and the thickness of the skin around the eyes is only one fourth of that of the face; meanwhile, loose connective tissue is arranged on the dermis layer of the skin around the eyes, and the dermis layer is rich in microvascular and lymphatic nerve tissues and sensitive to external stimulation. Therefore, the facial acne-removing product cannot be used directly instead of the periocular product, and the periocular product is milder and does not irritate when being effective compared with the facial product.
In practical researches, the applicant finds that the conventional acne removing product is mainly aimed at the face or other parts, and is rarely used for removing acnes from the skin around eyes. Meanwhile, most products on the market use components with larger irritation such as salicylic acid and the like to achieve the acne removing effect, and have larger irritation to the eyes.
In view of the above, the present invention is intended to provide an eye acne-removing product which has an acne-removing effect, is fine in appearance, and does not irritate the eye Zhou Wenhe.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention aims to provide an anti-acne composition for eyes without irritation and application of specific eye cream thereof, and the double requirements of anti-acne and skin care for the skin around eyes are realized by multi-dimension skin care.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
in a first aspect, the invention provides an anti-acne composition for eye irritation, which is prepared from the following components in parts by weight:
in the technical scheme, the lotus oil-control anti-inflammatory factor comprises an Egypt blue water lily flower extract and a lotus flower extract, and the specific commodity name is Nelupure. The lotus oil-controlling anti-inflammatory factor can reduce the expression of leptin receptor in sebaceous gland cells, inhibit excessive secretion of sebum, reduce various skin blemishes, and solve the problems of inflammatory (pustule/acne) and non-inflammatory (blackhead and whitehead) skin.
In the above technical scheme, the skin ecological factor comprises broom She Ao African tea branch/leaf oil, cortex Magnolia officinalis bark extract, and fructus Piperis seed extract, and the specific trade name is CutiBiome CLR. The modified skin ecological factor is a synergistic compound of various lipophilic extracts, and sources include Manuka, black pepper and magnolia, can reduce sebum generation, reduce film forming activity of acne bacillus toxic strains and obviously inhibit growth of acne bacillus toxic strains, can modify the skin ecological system, and helps to restore natural health balance of skin microbiota.
In the technical scheme, the allantoin has the effects of increasing the water resultant force and preventing the water loss, and has the effects of smoothing and tendering the skin. Can relieve xerosis cutis, promote cell regeneration, promote skin metabolism, and promote healing. Can be used for treating seborrheic infection, ichthyosis, and skin injury. Has good therapeutic effect on rhagadia manus et pedis.
In the technical scheme, zinc carbonate hydroxide, pearl powder, amber powder and borneol are all derived from the eight-treasure ancient prescription inherited by the maple for 400 years, wherein the zinc carbonate hydroxide has the effects of detoxification, improving eyesight, removing nebula, astringing dampness, relieving itching and healing sore, can partially absorb wound surface secretion, can inhibit the growth of local staphylococcus, and has better anti-corrosion, astringing and protecting effects on skin inflammation and surface wound; the pearl has the effects of relieving heart and tranquillization, clearing heat and nourishing yin, removing nebula and improving eyesight, and detoxifying and promoting granulation, and can be used for resolving toxin, resolving malignant boil, and eliminating internal ulcer; amber is a hydrocarbon compound formed by burying resin of ancient Pinaceae plants in underground for long-term condensation, and has the effects of relieving convulsion, tranquillizing, removing blood stasis, stopping bleeding, treating carbuncle, sore, traumatic injury, stopping bleeding and promoting granulation; the borneol has better antibacterial and anti-inflammatory effects, can generally increase the permeability of capillaries of a human body, eliminates various inflammations in the body of a patient, has the effects of inducing resuscitation and refreshing mind, clearing heat and relieving pain, and has the effect of promoting granulation on the human body.
In the technical scheme, the radix ampelopsis extract has the effects of clearing heat and detoxicating, resolving hard mass and relieving pain, promoting tissue regeneration and healing sore, has antibacterial effect, and can be used for treating suppurative dermatosis; the bletilla striata root extract has the effects of whitening and removing freckles, astringing and stopping bleeding, and reducing swelling and promoting granulation, is a good medicine for beautifying and is known as 'beautifying Bai Xianzi', can be rubbed externally, can clear acne on the face and leave marks, moisten and whiten skin, and make the skin smooth like jade; the tuckahoe sclerotium extract has the effect of promoting proliferation, integrin and the like, the integrin can reflect the proliferation condition of fiber bud cells and the adhesion condition between cells and between fibrin, and the proliferation of the integrin can reduce the diameter and the volume of collagen wrapped by the fiber bud cells, so that the tuckahoe sclerotium extract has the effect of shrinkage, and also has the antibacterial property, anti-inflammatory property and moisture retention property, and has good inhibition effect on various bacteria and fungi.
In a second aspect, the invention provides an anti-acne eye cream for eyes without irritation, which is prepared from the anti-acne composition and auxiliary materials.
In order to improve the organoleptic properties, impart nutrition to the skin, prevent deterioration of quality, etc., various components generally used in eye cosmetics other than the above components may be added to the composition of the present invention as needed within a range that does not impair the effects of the present invention. Preferably, the auxiliary materials are selected from one or more of polyalcohol, humectant, skin-moistening grease, emulsifying agent, thickener, stabilizer, antioxidant, metal ion chelating agent, antiseptic, pH regulator, antioxidant and deionized water.
In the above technical solution, the emollient oil may be one or more selected from shea butter, phytosterol isostearate, hydrogenated polydecene, synthetic squalane, isononyl isononanoate, polydimethylsiloxane, dimethiconol, cetylstearyl alcohol, isohexadecane, and cyclopentadimethicone. Preferably, the skin-moistening grease is a composition of polydimethylsiloxane and polydimethylsiloxane alcohol, and the compatibility selection of the grease can greatly reduce the phenomenon of silica gel agglomeration in the heating process after other grease is introduced.
In the above technical solution, the stabilizer is preferably a high molecular polymer thickener, such as hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer/sorbitan isostearate, with the trade name of SEPINOV WEO, and polyacrylamide/polyethylene glycol diacrylate with the trade name of SEPIGEL 305.
In the above technical scheme, the emulsifier is preferably cetostearyl olive oleate/sorbitan olive oleate, a mixture of Olivem1000 and PEG-100 stearate. The long carbon chain composition of Olivem1000 is similar to the composition of skin sebum, has bionic similarity, can promote the barrier function of skin, and the selected emulsifier is olive-derived liquid crystal emulsifier, is friendly to skin and has high moisturizing effect proved by researches.
In the above technical solution, the thickener is one or more selected from pentaerythritol distearate, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, cetostearyl alcohol and beeswax.
In the above technical scheme, the metal ion chelating agent is selected from one or more of disodium EDTA, EDTA and tetrasodium EDTA.
In the above technical scheme, the polyol is selected from one or more of glycerol, propylene glycol, butylene glycol, sorbitol, dipropylene glycol, 1, 3-propanediol, pentanediol and hexanediol.
In the above technical scheme, the antioxidant is selected from one or more of tocopherols, dibutyl hydroxy toluene, butyl hydroxy anisole and gallates, preferably tocopherol acetate.
In the technical scheme, the preservative is one or more selected from phenoxyethanol, ethylhexyl glycerol, chlorphenicol, methylparaben, p-hydroxyacetophenone, propylparaben, 1, 2-hexanediol and sorbitan octoate.
In a third aspect, the invention provides a preparation method of the acne-removing eye cream, which comprises the following steps:
s1, adding water, a metal ion chelating agent and allantoin into an emulsifying tank, stirring and heating to 75-85 ℃ until the materials are completely dissolved;
s2, adding skin-moistening grease, an emulsifier, a first part of preservative, a thickener and an antioxidant into an oil phase pretreatment tank, stirring and heating to 75-85 ℃ until the materials are completely dissolved, and obtaining an oil phase;
s3, adding a first part of polyol, zinc carbonate hydroxide, amber powder and pearl powder into the oil phase obtained in the step S2, and stirring until the materials are completely and uniformly dispersed to obtain an intermediate product 1;
s4, filtering the intermediate product 1 obtained in the step S3 into the material in the step S1, homogenizing, stirring and vacuumizing; after homogenization, stirring continuously until the material is uniform, and then cooling to T 1 Intermediate 2;
s5, adding borneol and a stabilizer into the intermediate product 2 obtained in the step S4, and vacuumizing, homogenizing and stirring until the materials are uniformly mixed; then cooling down again to T 2 Adding radix Ampelopsis extract, rhizoma Bletillae extract, poria sclerotium extract, flos Nelumbinis oil-controlling antiinflammatory factor, skin ecological factor correction, and second part of polyalcohol into 200 mesh sieve, and vacuum homogenizing under stirring until the materials are mixed uniformly; then cooling down again to T 3 Adding a second part of preservative through a 200-mesh filter screen, maintaining vacuum homogenizing and stirring until the materials are uniformly mixed, and continuously cooling to T 4 Stopping stirring below deg.C to obtain the final product.
As a further preferable mode of the above technical scheme, T 1 At 55-60 ℃, T 2 50-55 ℃, T 3 At 40-45 ℃, T 4 38 ℃.
In a fourth aspect, the invention provides an application of the acne-removing composition in preparing an eye acne-removing cosmetic.
Compared with the prior art, the invention has the following beneficial effects:
(1) The acne-removing composition and the eye cream provided by the invention have high applicability to Zhou Qu acne, are mild and do not irritate eyes.
(2) The acne-removing composition provided by the invention mainly plays roles in removing acnes, repairing and preserving moisture, and specifically:
acne-removing efficacy: the functional components are mainly added around the three aspects of inhibiting inflammation, inhibiting sebum secretion and improving skin microecology; the zinc carbonate hydroxide and the pearl powder in the composition have the effects of absorbing and drying dampness, can jointly act to absorb exudates on the acne wound surface, and can also damage the living environment of toxic acne bacillus in skin hair follicles, so that the reproduction of the toxic acne bacillus is reduced, and the formation of acne lesions is reduced; the anti-inflammatory and antibacterial effects of borneol and the hemostatic and bactericidal effects of amber can be combined so as to achieve deep anti-inflammatory effect and promote the healing of the wound surface of the acne; the composition can greatly inhibit sebum secretion under the synergistic effect of lotus oil-control anti-inflammatory factors and skin ecological factor correction, reduce the lipid content in sebum, which causes inflammatory injury and acne, reduce the film-forming activity of acne bacillus toxic strains and obviously inhibit the growth of the acne bacillus toxic strains, and also can correct the skin ecological system and help restore the natural healthy balance of skin microbiota.
The repairing effect aspect is as follows: firstly, through grease coverage, the percutaneous water loss is reduced; in addition, the pH value of the product is controlled to maintain the pH value of the weak acidic environment of the skin, and the product is regulated to be weak acidic by utilizing zinc carbonate hydroxide without using a conventional sodium hydroxide pH regulator, so that the product has better skin barrier enhancement function.
Moisture retention efficacy aspect: the moisture-keeping and water-locking component allantoin is added to balance the water and oil, so that the healthy state of the skin around eyes is achieved.
(3) The preparation method provided by the invention is simple and is easy for large-scale production of products.
Drawings
FIG. 1 is an oil phase dispersion comparative graph of comparative example 1 and example 4 of the present invention; wherein, the left graph is the oil phase of the pure silicone oil system, and the right graph is the oil phase of other systems.
FIG. 2 is a graph showing the results of the chick embryo stimulation test of comparative example 2 and example 4 according to the present invention; wherein, the left graph is a test chart of the product of the comparative example 2, and the right graph is a test chart of the product of the example 4.
FIG. 3 is a graph showing the comparison of the human efficacy evaluation test effects of the product of example 4 of the present invention before and after use.
Detailed Description
The following description of the embodiments of the present invention will clearly and fully describe the technical aspects of the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, are intended to fall within the scope of the present invention.
It should be noted that, in the present invention, part of the substance information is as follows:
the lotus flower oil-controlling anti-inflammatory factor used in the invention is a mixture of a flower extract of Egypt blue water lily (NYMPHAEA COERULEA) and a flower extract of lotus (Nelumbo NUCIFERA), and the manufacturer of the lotus flower oil-controlling anti-inflammatory factor is PROVITAL, S.A.U, and the specific trade name is Nelumpule.
The skin ecological factor correction agent used in the invention is a mixture of broom leaf Australian tea (LEPTOSPERMUM SCOPARIUM) branch/leaf oil, magnolia bark extract (MAGNOLIA OFFICINALIS) and pepper (PIPER NIGRUM) seed extract, and the manufacturer of the skin ecological factor correction agent is Germany CLR, and the specific trade name is CutiBiome CLR.
The product name of the hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer/sorbitan isostearate used in the invention is SEPINOV TM WEO。
The trade name of cetostearyl oleate/sorbitan olive oleate used in the present invention is Olivem1000.
The phenoxyethanol/ethylhexyl glycerol used in the present invention is sold under the trade name euxyl PE 9010.
Example 1
An anti-acne composition for non-irritating eyes is prepared by dispersing the following components in a solvent according to mass:
example 2
An anti-acne composition for non-irritating eyes is prepared by dispersing the following components in a solvent according to mass:
example 3
An anti-acne composition for non-irritating eyes is prepared by dispersing the following components in a solvent according to mass:
example 4
An anti-acne eye cream for non-irritation of eyes is prepared from the following raw materials in mass:
table 1 composition of the raw materials in example 4
In this embodiment, a method for preparing an anti-acne eye cream is also provided, including the following steps:
s1, adding water, a metal ion chelating agent and allantoin (namely phase A) into an emulsifying tank, stirring and heating to 80 ℃ until the materials are completely dissolved;
s2, adding skin-moistening grease, an emulsifier, a first part of preservative, a thickening agent and an antioxidant (namely phase B) into an oil phase pretreatment tank, stirring and heating to 79 ℃ until materials are completely dissolved, so as to obtain an oil phase;
s3, adding a first part of polyol, zinc carbonate hydroxide, amber powder and pearl powder (namely phase C) into the oil phase obtained in the step S2, and stirring until the materials are completely and uniformly dispersed to obtain an intermediate product 1;
s4, filtering the intermediate product 1 obtained in the step S3 into the material in the step S1, homogenizing, stirring and vacuumizing; continuously stirring until the material is uniform after homogenization is finished, and then cooling to 55 ℃ to obtain an intermediate product 2;
s5, adding borneol and a stabilizer (namely D phase) into the intermediate product 2 obtained in the step S4, and vacuumizing, homogenizing and stirring until materials are uniformly mixed; then cooling to 50deg.C again, adding radix Ampelopsis extract, rhizoma Bletillae extract, poria sclerotium extract, flos Nelumbinis oil-controlling antiinflammatory factor, skin ecological factor correction, and second part of polyalcohol (i.e. E phase) via 200 mesh sieve, and vacuum homogenizing under stirring until the materials are mixed uniformly; then cooling to 45 ℃ again, adding a second part of preservative (namely F phase) through a 200-mesh filter screen, keeping vacuum homogenizing and stirring until the materials are uniformly mixed, continuously cooling to below 38 ℃, and stopping stirring to obtain the acne removing eye cream.
Example 5
An anti-acne eye cream for non-irritation of eyes is prepared from the following raw materials in mass:
table 2 composition of the raw materials in example 5
In this embodiment, a method for preparing an anti-acne eye cream is also provided, including the following steps:
s1, adding water, a metal ion chelating agent and allantoin (namely phase A) into an emulsifying tank, stirring and heating to 80 ℃ until the materials are completely dissolved;
s2, adding skin-moistening grease, an emulsifier, a first part of preservative, a thickening agent and an antioxidant (namely phase B) into an oil phase pretreatment tank, stirring and heating to 79 ℃ until materials are completely dissolved, so as to obtain an oil phase;
s3, adding a first part of polyol, zinc carbonate hydroxide, amber powder and pearl powder (namely phase C) into the oil phase obtained in the step S2, and stirring until the materials are completely and uniformly dispersed to obtain an intermediate product 1;
s4, filtering the intermediate product 1 obtained in the step S3 into the material in the step S1, homogenizing, stirring and vacuumizing; continuously stirring until the material is uniform after homogenization is finished, and then cooling to 55 ℃ to obtain an intermediate product 2;
s5, adding borneol and a stabilizer (namely D phase) into the intermediate product 2 obtained in the step S4, and vacuumizing, homogenizing and stirring until materials are uniformly mixed; then cooling to 50deg.C again, adding radix Ampelopsis extract, rhizoma Bletillae extract, poria sclerotium extract, flos Nelumbinis oil-controlling antiinflammatory factor, skin ecological factor correction, and second part of polyalcohol (i.e. E phase) via 200 mesh sieve, and vacuum homogenizing under stirring until the materials are mixed uniformly; then cooling to 45 ℃ again, adding a second part of preservative (namely F phase) through a 200-mesh filter screen, keeping vacuum homogenizing and stirring until the materials are uniformly mixed, continuously cooling to below 38 ℃, and stopping stirring to obtain the acne removing eye cream.
Example 6
An anti-acne eye cream for non-irritation of eyes is prepared from the following raw materials in mass:
TABLE 3 composition of the raw materials in example 6
In this embodiment, a method for preparing an anti-acne eye cream is also provided, including the following steps:
s1, adding water, a metal ion chelating agent and allantoin (namely phase A) into an emulsifying tank, stirring and heating to 80 ℃ until the materials are completely dissolved;
s2, adding skin-moistening grease, an emulsifier, a first part of preservative, a thickening agent and an antioxidant (namely phase B) into an oil phase pretreatment tank, stirring and heating to 79 ℃ until materials are completely dissolved, so as to obtain an oil phase;
s3, adding a first part of polyol, zinc carbonate hydroxide, amber powder and pearl powder (namely phase C) into the oil phase obtained in the step S2, and stirring until the materials are completely and uniformly dispersed to obtain an intermediate product 1;
s4, filtering the intermediate product 1 obtained in the step S3 into the material in the step S1, homogenizing, stirring and vacuumizing; continuously stirring until the material is uniform after homogenization is finished, and then cooling to 55 ℃ to obtain an intermediate product 2;
s5, adding borneol and a stabilizer (namely D phase) into the intermediate product 2 obtained in the step S4, and vacuumizing, homogenizing and stirring until materials are uniformly mixed; then cooling to 50deg.C again, adding radix Ampelopsis extract, rhizoma Bletillae extract, poria sclerotium extract, flos Nelumbinis oil-controlling antiinflammatory factor, skin ecological factor correction, and second part of polyalcohol (i.e. E phase) via 200 mesh sieve, and vacuum homogenizing under stirring until the materials are mixed uniformly; then cooling to 45 ℃ again, adding a second part of preservative (namely F phase) through a 200-mesh filter screen, keeping vacuum homogenizing and stirring until the materials are uniformly mixed, continuously cooling to below 38 ℃, and stopping stirring to obtain the acne removing eye cream.
Example 7
An anti-acne eye cream for non-irritation of eyes is prepared from the following raw materials in mass:
TABLE 4 composition of the raw materials in example 7
In this embodiment, a method for preparing an anti-acne eye cream is also provided, including the following steps:
s1, adding water, a metal ion chelating agent and allantoin (namely phase A) into an emulsifying tank, stirring and heating to 80 ℃ until the materials are completely dissolved;
s2, adding skin-moistening grease, an emulsifier, a first part of preservative, a thickening agent and an antioxidant (namely phase B) into an oil phase pretreatment tank, stirring and heating to 79 ℃ until materials are completely dissolved, so as to obtain an oil phase;
s3, adding a first part of polyol, zinc carbonate hydroxide, amber powder and pearl powder (namely phase C) into the oil phase obtained in the step S2, and stirring until the materials are completely and uniformly dispersed to obtain an intermediate product 1;
s4, filtering the intermediate product 1 obtained in the step S3 into the material in the step S1, homogenizing, stirring and vacuumizing; continuously stirring until the material is uniform after homogenization is finished, and then cooling to 55 ℃ to obtain an intermediate product 2;
s5, adding borneol and a stabilizer (namely D phase) into the intermediate product 2 obtained in the step S4, and vacuumizing, homogenizing and stirring until materials are uniformly mixed; then cooling to 50deg.C again, adding radix Ampelopsis extract, rhizoma Bletillae extract, poria sclerotium extract, flos Nelumbinis oil-controlling antiinflammatory factor, skin ecological factor correction, and second part of polyalcohol (i.e. E phase) via 200 mesh sieve, and vacuum homogenizing under stirring until the materials are mixed uniformly; then cooling to 45 ℃ again, adding a second part of preservative (namely F phase) through a 200-mesh filter screen, keeping vacuum homogenizing and stirring until the materials are uniformly mixed, continuously cooling to below 38 ℃, and stopping stirring to obtain the acne removing eye cream.
Comparative example 1
Compared with the example 4, in the step S2, the polydimethylsiloxane in the B phase is replaced by isononyl isononanoate which is not silicone oil or synthesized squalane, and the fact that the polydimethylsiloxane alcohol is heated at high temperature in the oil phase to form floccules is found to be very easy, and after a pure silicone oil system is selected, a clear and transparent oil phase can be obtained, the flocculation is avoided, the process is easy to operate, and the subsequently prepared eye cream has silky skin feel and is especially suitable for the eyes. The specific comparison chart is shown in fig. 1.
This is because tocopheryl acetate and shea butter in the oil phase are more difficult to be compatible with the other ingredients in the oil phase and therefore the oil phase needs to be screened experimentally.
Comparative example 2
Compared with the example 4, the difference is that the common acne removing component salicylic acid is added into the A phase in the step S1, the salicylic acid dosage is 1g, the water dosage is 59g, the other steps and the raw material dosage are consistent, and the prepared eye cream has high irritation and is not suitable for the skin around the eyes.
Comparative example 3
Compared with the example 4, the difference is that zinc carbonate hydroxide, amber powder and pearl powder are not added in the C phase of the step S3, the prepared product is slightly acidic, and the product has certain irritation and poor acne removing effect.
Comparative example 4
Compared with the example 4, the difference is that no lotus flower oil-controlling anti-inflammatory factor is added in the E phase of the step S5, the dosage of butanediol is 3.5g, and the acne-removing effect of the prepared product is poor.
Comparative example 5
Compared with example 4, the difference is that the E phase in the step S5 is not modified by skin ecological factors, the dosage of butanediol is 4g, and the acne removing effect of the prepared product is poor.
Test example 1: product pH detection
The pH value of the prepared product is 5-6 without using a pH value regulator in the embodiments 4-7, accords with the normal range of skin, is mild and has no stimulation, and is especially suitable for skin around eyes.
Comparative example 2 salicylic acid containing products have a pH of 3.8-4.2, are highly acidic and risk skin exfoliation; the pH value of the product prepared in the comparative example 3 is 4.5-4.8, the product has partial acidity and has certain irritation to skin, and pH value regulators such as sodium hydroxide and the like are required to be added for adjustment.
Test example 2: eye irritation test
The samples prepared in example 4 and comparative example 2 were subjected to eye irritation study according to the cosmetic eye irritation in vitro animal replacement test.
Test protocol: according to the standard SN/T2329-2009 cosmetic eye irritation/corrosiveness chick embryo chorioallantoic membrane test, specifically, 9-day-old SPF-grade chick embryo is selected, 0.3ml of a sample is directly contacted with chorioallantoic membrane CAM, the reaction is carried out for 3min,0.9% physiological saline washes out a paste, and vascular changes are observed after 30 s.
Investigation indexes: the evaluation was performed by using the end point scoring method (ES), and the time and extent of occurrence of three toxic end points of bleeding, coagulation and vascular thawing were examined, and the evaluation criteria of the end point scores are shown in table 5.
Table 5 evaluation of end point scoring results
| Endpoint evaluation | Irritation classification |
| ES≤12 | No/light irritation |
| 12＜ES＜16 | Moderate irritation |
| ES≥16 | Strong irritation/corrosiveness |
Test results: the sample prepared in the embodiment 4 of the invention has an ES value of 8, and the eye irritation is no/light irritation, and is especially suitable for periocular skin; the ES value obtained by calculation of the sample prepared from salicylic acid in comparative example 2 of the present invention was 16, and the eye irritation was strong, which was not very suitable for periocular skin. The comparison graph of the specific chick embryo effect is shown in figure 2.
Test example 3: human efficacy evaluation test
The test aims at researching the change of the skin physiological index before and after the target crowd continuously uses the product and evaluating the effect of the product so as to verify the efficacy of the product. The test environment is that the temperature is 20.0-21.8 ℃, the humidity is 42.8-54.1% RH, and the requirements of scheme design are met.
1.1 evaluation method
Subject inclusion criteria: 40 healthy subjects 18-35 years old were selected, ISGA was scored for 1-3 minutes, and the skin barrier around the eyes was fragile and self-described as dry.
The detection method comprises the following steps: the subjects 40 were divided into 4 groups of 10 persons each, and the 4 groups of products prepared in example 4 and comparative examples 3 to 5 were used as test products, and the test products were applied to the whole face of the subject with emphasis on the eyes. Long-term sun exposure, outdoor exercises, travel, etc. cannot be performed during the entire test period, and cosmetics or medicines having similar effects to those of the products must not be used, and the subjects must not change the daily care habits during the test period.
1.2 evaluation index
1.2.1 acne improvement Condition
The full face powder stabs of the test subjects are delineated before and after the test, the full face powder stabs are counted, descriptive statistics are carried out on each measured value, and the significance difference level before and after the test is checked.
1.2.2 subjective assessment of subjects
The subjects were each given a satisfaction evaluation of the product feel and skin condition after 14 days and 28 days of use of the product.
1.2.3 product safety in use assessment
Record whether adverse reaction symptoms, names of symptoms, degree of symptoms, starting time, duration and occurrence position of the symptoms.
1.3 evaluation results
1.3.1 evaluation results of pimple count
The results of the statistical evaluation of the full-face powder stick counts before and after the test of the subjects are shown in Table 6, and the comparison image of one subject before and after the use of the product of example 4 is shown in FIG. 3.
As can be seen, the acne in the subjects was significantly improved after 28 days of use of the product of example 4.
Table 6 results of skin acne counts before and after application of the product (x±s, n=10) to subjects
| Before using the product | After 28 days of using the product | Rate of change (%) | |
| Example 4 | 7.4±1.71 | 4.5±1.84** | -39.19 |
| Comparative example 3 | 7.1±2.28 | 5.6±1.71 | -21.13 |
| Comparative example 4 | 7.2±2.70 | 6.0±2.26 | -16.67 |
| Comparative example 5 | 7.1±2.60 | 5.9±2.42 | -16.90 |
( Compared to prior to use of the product, "x" indicates a statistical difference, P <0.05; "x" indicates significant statistical difference, P <0.01 )
As can be seen from table 6, the full face powder puncture count was significantly improved (39.19% reduction and p < 0.01) after 28 days using the test product prepared in the examples of the present invention, compared to before using the test product; the full face powder stab count was slightly improved after 28 days using the test product prepared in the comparative example of the present invention, but the statistical result was not significant (p > 0.05).
1.3.2 subjective assessment results of subjects
Satisfaction evaluation was performed on the product feel and skin condition, respectively, 28 days after the subject used the product, wherein satisfaction = sum of subjects selected (very clear/very satisfactory, more clear/more satisfactory × total effective number x 100%).
| Subjective evaluation index | Example 4 | Comparative example 3 | Comparative example 4 | Comparative example 5 |
| Acne count reduction | 100％ | 80％ | 70％ | 70％ |
| Pimple reduction in number | 80％ | 70％ | 60％ | 50％ |
| Papular volume reduction | 90％ | 80％ | 80％ | 70％ |
| Pi Fufan red improvement | 100％ | 80％ | 70％ | 70％ |
| Improvement of skin erythema | 80％ | 70％ | 80％ | 70％ |
| Improvement of skin dryness | 90％ | 90％ | 80％ | 90％ |
| Skin hydration enhancement | 90％ | 80％ | 80％ | 80％ |
| Skin gloss enhancement | 80％ | 70％ | 60％ | 70％ |
| Improvement of desquamation of skin | 90％ | 80％ | 80％ | 80％ |
| Improvement of skin roughness | 90％ | 80％ | 80％ | 80％ |
| Overall satisfaction | 100％ | 80％ | 70％ | 70％ |
1.3.3 results of product safety in use assessment
According to the use characteristics and the method noted by the label of the cosmetic product, the test product prepared in the example 4 and the test products prepared in the comparative examples 3-5 are directly used by a subject, skin reactions of the subject are followed once a week, and the result is recorded according to the classification standard of the human body trial skin adverse reaction in the current effective technical specification (2015 edition of cosmetic safety technical specification), and the trial time is 4 weeks (28 days). The test results of human body trial show that skin adverse reaction occurs in 0 cases among 40 patients participating in the test, and the safety of the product is higher.
The applicant states that the present invention describes the eye mask essence with whitening and repairing effects and the preparation method thereof through the above embodiments, but the present invention is not limited to the above embodiments, i.e. it does not mean that the present invention must be implemented by the above embodiments. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of individual raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
Claims (10)
1. The acne-removing composition for the non-irritation of eyes is characterized by being prepared from the following components in parts by weight:
2. the acne-removing composition for eye irritation-free according to claim 1, wherein the lotus oil-controlling anti-inflammatory factor comprises a blue lotus flower extract and a lotus flower extract.
3. The composition for the non-irritating eye of claim 1, wherein said modified skin ecological factor comprises broom She Ao tea branch/leaf oil, magnolia bark extract, piper nigrum seed extract.
4. An anti-acne eye cream for non-irritating eyes, which is characterized by being prepared from the anti-acne composition according to any one of claims 1-3 and auxiliary materials.
5. The non-irritating acne-removing eye cream of claim 4, wherein said adjuvants are selected from one or more of moisturizers, emollient oils, emulsifiers, thickeners, stabilizers, antioxidants, metal ion chelators, preservatives, pH adjusters, antioxidants, deionized water, polyols.
6. The non-irritating acne-removing eye cream of claim 5, wherein said emollient oil is selected from one or more of shea butter, phytosterol isostearate, hydrogenated polydecene, synthetic squalane, isononyl isononanoate, polydimethylsiloxane, dimethiconol, cetostearyl alcohol, isohexadecane, cyclopentadimethicone;
the stabilizer is a high molecular polymer thickener;
the emulsifier is cetostearyl oleate/sorbitan oleate;
the thickening agent is one or more of pentaerythritol distearate, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, cetostearyl alcohol and beeswax;
the metal ion chelating agent is selected from one or more of disodium EDTA, EDTA and tetrasodium EDTA;
the polyalcohol is one or more of glycerol, propylene glycol, butanediol, sorbitol, dipropylene glycol, 1, 3-propanediol, pentanediol and hexanediol;
the antioxidant is one or more selected from tocopherols, dibutyl hydroxy toluene, butyl hydroxy anisole and gallic acid esters;
the preservative is one or more selected from phenoxyethanol, ethylhexyl glycerol, chlorpheniramine, methylparaben, p-hydroxyacetophenone, propylparaben, 1, 2-hexanediol and sorbitan octoate.
7. The acne-removing eye cream for non-irritation to eyes according to claim 5 or 6, wherein the following auxiliary materials are used in the following amounts in parts by weight: 2 to 15 parts of polyalcohol, 2 to 20 parts of skin-moistening grease, 2 to 10 parts of emulsifying agent, 1 to 6 parts of thickening agent, 0.5 to 3 parts of antioxidant, 0.1 to 1 part of metal ion chelating agent, 0.2 to 3 parts of preservative and 30 to 95 parts of deionized water.
8. A method for preparing the acne-removing eye cream according to any one of claims 4 to 7, comprising the steps of:
s1, adding water, a metal ion chelating agent and allantoin into an emulsifying tank, stirring and heating to 75-85 ℃ until the materials are completely dissolved;
s2, adding skin-moistening grease, an emulsifier, a first part of preservative, a thickener and an antioxidant into an oil phase pretreatment tank, stirring and heating to 75-85 ℃ until the materials are completely dissolved, and obtaining an oil phase;
s3, adding a first part of polyol, zinc carbonate hydroxide, amber powder and pearl powder into the oil phase obtained in the step S2, and stirring until the materials are completely and uniformly dispersed to obtain an intermediate product 1;
s4, filtering the intermediate product 1 obtained in the step S3 into the material in the step S1, homogenizing, stirring and vacuumizing; after homogenization, stirring continuously until the material is uniform, and then cooling to T 1 Intermediate 2;
s5, adding borneol and a stabilizer into the intermediate product 2 obtained in the step S4, and vacuumizing, homogenizing and stirring until the materials are uniformly mixed; then cooling down again to T 2 Adding radix Ampelopsis extract, rhizoma Bletillae extract, poria sclerotium extract, flos Nelumbinis oil-controlling antiinflammatory factor, skin ecological factor correction, and second part of polyalcohol into 200 mesh sieve, and vacuum homogenizing under stirring until the materials are mixed uniformly; then cooling down again to T 3 Adding a second part of preservative through a 200-mesh filter screen, maintaining vacuum homogenizing and stirring until the materials are uniformly mixed, and continuously cooling to T 4 Stopping stirring below deg.C to obtain the final product.
9. The process according to claim 8, wherein T is 1 At 55-60 ℃, T 2 50-55 ℃, T 3 At 40-45 ℃, T 4 38 ℃.
10. Use of the acne-removing composition according to any one of claims 1 to 3 for the preparation of an eye acne-removing cosmetic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310301930.XA CN116421514A (en) | 2023-03-27 | 2023-03-27 | Acne-removing composition and eye cream for non-irritation of eyes, and preparation method and application of acne-removing composition and eye cream |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310301930.XA CN116421514A (en) | 2023-03-27 | 2023-03-27 | Acne-removing composition and eye cream for non-irritation of eyes, and preparation method and application of acne-removing composition and eye cream |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421514A true CN116421514A (en) | 2023-07-14 |
Family
ID=87080762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310301930.XA Pending CN116421514A (en) | 2023-03-27 | 2023-03-27 | Acne-removing composition and eye cream for non-irritation of eyes, and preparation method and application of acne-removing composition and eye cream |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421514A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115282168A (en) * | 2022-08-30 | 2022-11-04 | 马应龙大健康有限公司 | Soothing moisturizer for relieving infantile eczema symptom and preparation method and application thereof |
-
2023
- 2023-03-27 CN CN202310301930.XA patent/CN116421514A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115282168A (en) * | 2022-08-30 | 2022-11-04 | 马应龙大健康有限公司 | Soothing moisturizer for relieving infantile eczema symptom and preparation method and application thereof |
| CN115282168B (en) * | 2022-08-30 | 2024-05-31 | 马应龙大健康有限公司 | Soothing skin cream for relieving infant eczema symptoms and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108969429B (en) | Acne removing essence | |
| CN109157450B (en) | Acne-removing essence | |
| CN109157451B (en) | Acne-removing facial cleanser | |
| CN113304075B (en) | Glacier rock cleaning oil control mud film and preparation method thereof | |
| CN109260075B (en) | Acne-removing conditioning water | |
| CN105536027A (en) | Scar treatment strip capable of lowering tissue tension and preparation method thereof | |
| CN113693979B (en) | Oil-control acne-removing composition and application thereof | |
| CN111773272A (en) | External compound formula for treating acne and preparation method thereof | |
| CN111671692A (en) | Acne-removing composition and preparation method and application thereof | |
| CN113332160A (en) | Cosmetic composition for conditioning peritrichotic skin | |
| CN116421514A (en) | Acne-removing composition and eye cream for non-irritation of eyes, and preparation method and application of acne-removing composition and eye cream | |
| CN115919733A (en) | Cosmetic composition for removing acne and preparation method thereof | |
| CN108295022B (en) | Acne-removing composition and preparation method thereof | |
| CN112516066B (en) | Oil control composition and application thereof in cosmetics | |
| CN106137839A (en) | A kind of acne-removing liquid | |
| CN112402308A (en) | Multi-effect relieving moisturizing lotion and preparation method thereof | |
| CN116459169B (en) | Anti-inflammatory moisturizing skin external composition and preparation method and application thereof | |
| KR101459742B1 (en) | Cosmetic composition for improving acne containing extracts of natural substance | |
| CN110025508A (en) | A kind of essence cream and preparation method thereof preventing striae of pregnancy generation | |
| CN116115528A (en) | Composition for relieving, repairing and moisturizing as well as application and preparation method thereof | |
| CN115919686A (en) | Skin soothing lotion for enhancing skin barrier and preparation method thereof | |
| CN113116753B (en) | Rose essential oil face cream and preparation method thereof | |
| CN106511153B (en) | Nanometer composition with acne removing effect and cosmetic or skin care product thereof | |
| CN112807238A (en) | Anti-inflammatory and soothing repair gel for skin and preparation method thereof | |
| CN110755343A (en) | Emulsion for old people and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |